While in endometrial cancer [15, 35] and gliomas [47] PTEN loss of function results in impaired HR DNA repair and sensitivity to PARP inhibitors, similar effects have not been observed in non-small cell lung cancer and prostate cancer [20, 49]. This evidence concerns the gene PTEN and Familial prostate cancer.